Director, Translational Science

Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe endocrine, metabolic, oncologic and neurological disorders by modulating the effects of the hormone cortisol. Since 2012, we have marketed Korlym® for the treatment of patients suffering from Cushing’s syndrome, a life-threatening orphan disorder caused by excess cortisol activity. In 2022, we generated revenue of $402 million and net income of $101 million.

We have discovered a portfolio of more than 1,000 proprietary selective cortisol modulators.  Our lead compounds are in Phase 2 and Phase 3 trials for the treatment of patients with Cushing’s syndrome, advanced ovarian cancer, castration-resistant prostate cancer and amyotrophic lateral sclerosis (“ALS”).  We plan to initiate a Phase 2b trial in patients with non-alcoholic steatohepatitis (“NASH”) by the end of this year.  Every year, we advance new molecules to the clinic.

Over the next few years, we expect to submit several new drug applications.

The Director, Translational Science will be responsible for designing and implementing biomarker strategies to deepen our understanding of cortisol modulation for the treatment of oncologic disease (primarily solid tumors) and endocrinology focusing on an asset already in clinical trials for the treatment of platinum-resistant ovarian cancer, prostate cancer and pancreatic cancer, and Cushings Disease.  This work will inform future clinical development plans as well as the mechanism of action and potential companion diagnostics.

Responsibilities:

• Nonclinical Research
  • Design and analyze non-clinical experiments to understand the biological role of glucocorticoids in oncologic and Cushings disease
  • Generate decisional data via contract research vendors and academic collaborators
  • Communicating findings with internal project teams, collaborators, and public publications
• Biomarker research
  • Design and analyze clinical biomarker assays for oncologic and endocrinology disease clinical trials with selective glucocorticoid receptor modulators
  • Work with biomarker operations and clinical operations colleagues to ensure implementation of biomarker strategy through review of clinical protocols, contracts, eCRFs, DTAs, ICFs, lab manuals, TLFs, and CSRs
  • Conduct exploratory biomarker data analyses
  • Coordinate formal biomarker analyses with biometrics, biostatistics, clinical data management, and external biomarker analysis teams
• General
  • Manage direct report(s) responsible for sample management across all Corcept programs
  • Author patents, publications, and posters related to research activities
  • Partner with the regulatory team to author/lead relevant nonclinical and clinical content for regulatory submissions, including INDs, IBs, NDAs, etc
  • Adhere to agreed timelines and budgets to ensure timely and cost-effective execution of deliverables
  • Provide disease-biology expertise in cross-functional teams and collaborate with other team members

Preferred Education and Experience:

• Ph.D. in Cell or Molecular Biology (or a related discipline) with 5+ years of industry experience
• Experience in performing and critically analyzing and interpreting both pre-clinical and clinical data using different transcriptomic and proteomic techniques is required
• Proven track record of achievement, as evidenced by publications in peer-reviewed journals, authorship of patents, and internal and/or external scientific presentations
• Ability to balance execution of tasks required to accomplish goals while creating an environment of scientific curiosity and open exchange of ideas
• Display a consistently positive attitude with team members, scientific curiosity, and the drive to innovate and think creatively with courage, integrity, and respect

The pay range that the Company reasonably expects to pay for this position is $234,000 - $275,000; the pay ultimately offered may vary based on legitimate considerations, including job-related knowledge, skills, experience, and education.  An annual cash bonus and equity grants may be provided as part of the overall compensation package, in addition to a full range of medical, financial, and/or other wellness benefits, dependent on the position offered. 

Applicants must be currently authorized to work in the United States on a full-time basis.

If you are based in California, we encourage you to read this important information for California residents linked here.

Corcept appreciates the commitment and hard work of all our team members as we strive to discover and develop novel treatments for patients with serious unmet medical needs.

 Please visit our website at: https://www.corcept.com/

Corcept is an Equal Opportunity Employer